RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$791M
This Quarter Return
+12.07%
1 Year Return
+12.81%
3 Year Return
+98.32%
5 Year Return
+175.58%
10 Year Return
+579.5%
AUM
$1.23B
AUM Growth
+$1.23B
(+18%)
Cap. Flow
+$106M
Cap. Flow
% of AUM
8.59%
Top 10 Holdings %
Top 10 Hldgs %
30.7%
Holding
101
New
8
Increased
39
Reduced
39
Closed
6
Top Buys
| 1 |
Inspire Medical Systems
INSP
|
$22.2M |
| 2 |
Exact Sciences
EXAS
|
$21.8M |
| 3 |
Medtronic
MDT
|
$14.4M |
| 4 |
Novo Nordisk
NVO
|
$11.9M |
| 5 |
CVS Health
CVS
|
$11.6M |
Top Sells
| 1 |
UnitedHealth
UNH
|
$19.1M |
| 2 |
Elevance Health
ELV
|
$18.4M |
| 3 |
Oscar Health
OSCR
|
$11.4M |
| 4 |
Cigna
CI
|
$11.3M |
| 5 |
Alnylam Pharmaceuticals
ALNY
|
$9.67M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Industrials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Neurocrine Biosciences
NBIX
$13.5B
| $8.27M | 0.67% |
71,750
-3,805
| -5% | -$438K |
|
52
Ionis Pharmaceuticals
IONS
$9.64B
| $7.81M | 0.63% |
195,000
+65,000
| +50% | +$2.6M |
|
53
Evolent Health
EVH
$1.11B
| $7.49M | 0.61% |
265,000
+215,000
| +430% | +$6.08M |
|
54
Charles River Laboratories
CRL
$7.99B
| $7.39M | 0.6% |
37,500
+3,500
| +10% | +$689K |
|
55
Transmedics
TMDX
$3.65B
| $7.11M | 0.58% |
45,270
+31,770
| +235% | +$4.99M |
|
56
Immunovant
IMVT
$2.91B
| $6.93M | 0.56% |
243,000
+112,500
| +86% | +$3.21M |
|
57
BridgeBio Pharma
BBIO
$9.91B
| $6.82M | 0.55% |
268,000
+83,500
| +45% | +$2.13M |
|
58
Nurix Therapeutics
NRIX
$723M
| $6.74M | 0.55% |
300,000
+125,607
| +72% | +$2.82M |
|
59
Acadia Healthcare
ACHC
$2.15B
| $6.71M | 0.54% |
105,750
+65,926
| +166% | +$4.18M |
|
60
Viking Therapeutics
VKTX
$3.02B
| $6.49M | 0.53% |
102,500
-12,500
| -11% | -$791K |
|
61
BioNTech
BNTX
$24.1B
| $6.06M | 0.49% |
+51,000
| New | +$6.06M |
|
62
Encompass Health
EHC
$12.5B
| $5.9M | 0.48% |
61,000
+1,000
| +2% | +$96.6K |
|
63
DexCom
DXCM
$30.9B
| $5.83M | 0.47% |
87,000
-30,000
| -26% | -$2.01M |
|
64
Syndax Pharmaceuticals
SNDX
$1.39B
| $5M | 0.41% |
259,500
+31,000
| +14% | +$597K |
|
65
ESSA Pharma
EPIX
$11.2M
| $4.88M | 0.4% |
804,649
-1,405
| -0.2% | -$8.51K |
|
66
Janux Therapeutics
JANX
$1.38B
| $4.85M | 0.39% |
106,847
| – | – |
|
67
Geron
GERN
$893M
| $4.54M | 0.37% |
+1,000,000
| New | +$4.54M |
|
68
Dianthus Therapeutics
DNTH
$781M
| $4.11M | 0.33% |
+150,000
| New | +$4.11M |
|
69
Xencor
XNCR
$594M
| $4.1M | 0.33% |
203,750
-15,000
| -7% | -$302K |
|
70
Mirum Pharmaceuticals
MIRM
$3.75B
| $4.1M | 0.33% |
105,000
-29,250
| -22% | -$1.14M |
|
71
IDEAYA Biosciences
IDYA
$2.26B
| $4.04M | 0.33% |
127,500
+74,000
| +138% | +$2.34M |
|
72
TG Therapeutics
TGTX
$5.03B
| $4.01M | 0.33% |
171,500
-42,000
| -20% | -$982K |
|
73
Merus
MRUS
$5.04B
| $3.97M | 0.32% |
79,500
-11,000
| -12% | -$550K |
|
74
Alkermes
ALKS
$4.95B
| $3.72M | 0.3% |
133,000
-17,000
| -11% | -$476K |
|
75
Annexon
ANNX
$225M
| $3.32M | 0.27% |
560,000
-340,000
| -38% | -$2.01M |
|